RUBA AL ABDULLA-rekin lankidetzan egindako argitalpenak (8)

2023

  1. Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors

    Biochemical Pharmacology, Vol. 217

2020

  1. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1866, Núm. 5

  2. Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters

    Biochemical Pharmacology, Vol. 171

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

2017

  1. Molecular bases of chemoresistance in cholangiocarcinoma

    Current Drug Targets, Vol. 18, Núm. 8, pp. 889-900

  2. The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma

    Oncotarget, Vol. 8, Núm. 9, pp. 15846-15857

2016

  1. Mechanisms of resistance to chemotherapy in gastric cancer

    Anti-Cancer Agents in Medicinal Chemistry, Vol. 16, Núm. 3, pp. 318-334